Wednesday, September 21, 2016

EpiPen price-gouging scandal brings a closer look at Mylan

I'm happy to say that the EpiPen price-gouging scandal has stirred enough outrage to trigger several investigations into Mylan.

Mylan CEO Heather Bresch was called in to testify before the House Oversight Committee today.  She's claiming that they're not price-gouging, that they only make $50 off of each pen...

Sunday, September 18, 2016

Price gouging on insulin is a thing, too

Remember the EpiPen price gouging story I posted not long ago?  It's funny, when I posted the story I said, "It's not related to diabetes."  But now that EpiPen prices have attracted such widespread attention, people have now brought up how much the cost of insulin has risen in recent years, too.

The EpiPen wasn't alone: Price gouging on insulin draws outrage

The rise in prices on insulin probably isn't quite as dramatic as the rise in EpiPen prices -- 200 percent on insulin, according to the Journal of the American Medical Association, contrasted with more like 500 percent on the EpiPen, but it's still a serious increase that we absolutely should be questioning.